Clinical Trial Update: Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy and safety of MW032 in combination with Xgeva for bone metastases from solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Bone Metastases From Solid Tumors

Drugs mentioned

• MW032
• Xgeva (denosumab)

Snippet

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. | Conditions: Bone Metastases | Phase 3 | Status: COMPLETED